MML Investors Services LLC Sells 9,319 Shares of IQVIA Holdings Inc. $IQV

MML Investors Services LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 162,356 shares of the medical research company’s stock after selling 9,319 shares during the period. MML Investors Services LLC’s holdings in IQVIA were worth $36,597,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the 4th quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth about $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth about $27,000. Measured Wealth Private Client Group LLC purchased a new position in shares of IQVIA in the 3rd quarter worth about $30,000. Finally, Activest Wealth Management raised its position in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent analyst reports. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. HSBC set a $210.00 price target on IQVIA in a research report on Wednesday, June 3rd. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Mizuho set a $215.00 price target on IQVIA in a research report on Monday, February 23rd. Finally, Evercore reissued an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $224.13.

IQVIA Price Performance

NYSE IQV opened at $178.07 on Tuesday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The firm has a market capitalization of $29.72 billion, a P/E ratio of 22.07, a PEG ratio of 1.56 and a beta of 1.21. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50-day moving average price of $173.65 and a 200-day moving average price of $193.06.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.